| ［1］ Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4related disease［J］. Mod Pathol, 2012, 25(9): 11811192. DOI: 10.1038/modpathol.2012.72.
［2］ FranklandSearby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy［J］. Biochim Biophys Acta, 2012, 1825(1): 6476. DOI: 10.1016/j.bbcan.2011.10.003.
［3］ Wang M. Comparative mechanisms of action of proteasome inhibitors［J］. Oncology (Williston Park), 2011, 25 Suppl 2: 1924.
［4］ Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOPrituximab for previously untreated diffuse large Bcell lymphoma and mantle cell lymphoma［J］. J Clin Oncol, 2011, 29(6): 690697. DOI: 10.1200/JCO.2010.31.1142.
［5］ Houot R, Le Gouill S, Ojeda Uribe M, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as firstline therapy for elderly mantle cell lymphoma patients: results of a phase Ⅱ trial from the GOELAMS［J］. Ann Oncol, 2012, 23(6): 15551561. DOI: 10.1093/annonc/mdr450.
［6］ Goy A, Younes A, Mclaughlin P, et al. Phase Ⅱ study of proteasome inhibitor bortezomib in relapsed or refractory Bcell nonHodgkin′s lymphoma［J］. J Clin Oncol, 2005, 23(4): 667675. DOI: 10.1200/JCO.2005.03.108.
［7］ O′Connor OA, Wright J, Moskowitz C, et al. Phase Ⅱ clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent nonHodgkin′s lymphoma and mantle cell lymphoma［J］. J Clin Oncol, 2005, 23(4): 676684. DOI: 10.1200/JCO.2005.02.050.
［8］ Mounier N, Ribrag V, Haioun C, et al. Efficacy and toxicity of two schedules of RCHOP plus bortezomib in frontline B lymphoma patients: a randomized phase Ⅱ trial from the Groupe d′Etude des Lymphomes de l′Adulte (GELA)［J］. Proc Am Soc Clin Oncol, 2007, 25: abstract 8010.
［9］ Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large Bcell lymphoma［J］. Blood, 2009, 113(24): 60696076. DOI: 10.1182/blood200901199679.
［10］ Zinzani PL, Tani M, Musuraca G, et al. Phase Ⅱ study of proteasome inhibitor bortezomib (Velcade (R)) in patients with relapsed/refractory Tcell lymphoma: preliminary results［J］. Blood, 2006, 108(11, 1): 697A.
［11］ Mai W, Meng H, Jin J, et al. Treatment with bortezomib in a patient with heavily pretreated refractory Tcell lymphoblastic lymphoma［J］. Eur J Haematol, 2006, 77(5): 445447. DOI: 10.1111/j.09024441.2006.t011EJH2889.x.
［12］ Otrock ZK, Hatoum HA, Salem ZM, et al. Longterm remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and highdose CHOPlike chemotherapy followed by autologous peripheral stem cell transplantation［J］. Ann Hematol, 2008, 87(12): 10231024. DOI: 10.1007/s0027700805237. |
